Previous close | 9.90 |
Open | 10.20 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 9.90 - 9.90 |
52-week range | 6.62 - 15.78 |
Volume | |
Avg. volume | 1,941 |
Market cap | 6.093B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | 41.26 |
EPS (TTM) | 0.24 |
Earnings date | 07 Nov 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 03 June 2021 |
1y target est | N/A |
As global markets react to China's robust stimulus measures, U.S. stocks have reached record highs, buoyed by optimism in technology sectors and AI demand, despite some mixed economic indicators such as consumer confidence and housing data. In this context of heightened market activity and evolving economic conditions, identifying high growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and shifts in consumer behavior driven...
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen’s recombinant polyclonals are part of Grifols’ robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals SAN CARLOS, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody
(Bloomberg) -- A group of Grifols SA investors including Flat Footed LLC, Mason Capital Management LLC and Sachem Head Capital Management LP is seeking a seat on the Spanish drugmaker’s board.Most Read from BloombergAOC Proposes $30 Billion Social Housing AuthorityThe Moonshot Plan to Eliminate Deaths on America’s RoadsCalifornia’s Anti-Speeding Bill Can Be a Traffic Safety BreakthroughNew York City’s Transit System Plans $65.4 Billion of Upgrades for Grand Central, SubwaysTo Build a Happier Cit